MEDICATION REFERENCE · REVIEW DRAFT
Mounjaro: source schedule reference
Research reference only. Source-reported examples and schedules are not dosing recommendations from MGMT Research. They do not establish safety or suitability. Prescribed medication decisions belong with a licensed clinician and the current product label.
Reference notes
Mounjaro is a branded tirzepatide product. This page records the source schedule for review; it does not prescribe a dose or equate an MGMT research vial with the branded medicine.
The source lists weekly doses of 2.5, 5, 7.5, 10, 12.5, 15 mg. It describes increases about every 4 weeks.
Mounjaro is a trademark of Eli Lilly; MGMT does not claim manufacturer affiliation.
| Vial | Diluent | Target | Volume | U-100 units |
|---|---|---|---|---|
| 10 mg | 2 mL | 2,500 mcg | 0.50 mL | 50 |
Source & content review 3 notes
This is an original, concise draft. Full information and numerical parity with the source is not yet established.
Open source reference ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source is a secondary summary; current product presentation, indication and prescribing details must be reconciled with the official label before publication.
- Source presents the brand as pens and contrasts it with compounded vials. Current official information includes branded vial presentations, so that framing is incomplete. Primary: https://pi.lilly.com/us/mounjaro-uspi.pdf
Captured source values
{
"numericalFacts": []
}